Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience


Yilmaz U., Yilmaz U., Yasar Z., Kirakli E. K. , Ulger S., Ozdogan Y., ...More

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.12, no.1, pp.334-339, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 1
  • Publication Date: 2016
  • Doi Number: 10.4103/0973-1482.163682
  • Journal Name: JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.334-339
  • Keywords: Concurrent chemoradiotherapy, nonsmall cell lung cancer, Stage III, survival, CONCURRENT THORACIC RADIOTHERAPY, THERAPY ONCOLOGY GROUP, RANDOMIZED PHASE-II, RADIATION-THERAPY, INDUCTION CHEMOTHERAPY, CONCOMITANT CHEMORADIOTHERAPY, SEQUENTIAL CHEMORADIOTHERAPY, ORAL VINORELBINE, CISPLATIN, TRIAL
  • Gazi University Affiliated: Yes

Abstract

Aim: Concurrent chemoradiotherapy (CRT) is the standard therapy for patients with unresectable Stage III nonsmall cell lung cancer (NSCLC). The aim of this study was to assess the efficacy and safety of concurrent CRT in unresectable Stage III NSCLC in Turkey.